Correlation between gene polymorphism of chromosome 3q26 rs12696304 and 1-year survival rate after acute heart failure in an elderly Han population in South China

doi:10.16150/j.1671-2870.2020.06.004

Abstract

Abstract:

Objective: To investigate the correlation between the gene polymorphism of rs12696304 in chromosome 3q26 and 1-year survival rate in the patients with acute heart failure (AHF). Methods: A total of 336 elderly patients of Han population in South China (aged≥60 years) with AHF were enrolled during March 2012 and April 2016. DNA of each patient was extracted from peripheral blood, and the gene polymorphism of rs12696304 was analyzed by real-time fluorescence quantitative PCR with TaqMan probe. One-year survival rate was compared between the patients with diffe-rent gene typing in multiple genetic models using Kaplan-Meier and log-rank test. The Cox regression analysis was used to assess relation between the gene polymorphism of rs12696304 and 1-year survival rate in the patients with AHF. Results: In the co-dominant genetic model, the 1-year survival rate of the AHF patients carrying heterozygous CG genotypes was lower than that of patients carrying wild homozygous GG genotypes (74.8% vs 85.4%, P=0.027). In the dominant genetic model, 1-year survival rate of the AHF patients carrying CG+CC genotype was significantly lower than that of patients carrying the wild homozygous GG genotype (74.9% vs 85.4%, P=0.023). Further Cox regression analysis showed that the risk of 1-year death in the AHF patients carrying CG+CC genotype was 2.45 times of that in the patients with GG genotype (HR=2.45, 95%CI: 1.22-4.95, P=0.012) after adjustment with the relevant variables in codominant model, and in the dominant model, the risk of 1-year death was also 2.45 times of that in patients with GG genotype (HR=2.45, 95%CI: 1.24-4.84, P=0.010). Conclusions: The gene polymorphisms of rs12696304 located in chromosome 3q26 region may be associated with the 1-year prognosis in the patients with AHF.

Key words: Single nucleotide polymorphism, 3q26 rs12696304, Acute heart failure, Prognosis

CLC Number:

R541.6

ZHANG Zhongwen, ZUO Xiangrong, ZHENG Xuhui, CAO Quan, Li Xinli, LI Yanxiu. Correlation between gene polymorphism of chromosome 3q26 rs12696304 and 1-year survival rate after acute heart failure in an elderly Han population in South China[J]. Journal of Diagnostics Concepts & Practice, 2020, 19(06): 565-571.

Figures/Tables 9

References 16

[1]	胡盛寿, 高润霖, 刘力生, 等. 《中国心血管病报告2018》概要[J]. 中国循环杂志, 2019, 34(3):209-220.
[2]	Yancy CW, Jessup M, Yancy CW, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines[J]. Circulation, 2013, 128(16):e240-e327.
[3]	Smith NL, Felix JF, Morrison AC, et al. Association of genome-wide variation with the risk of incident heart fai-lure in adults of European and African ancestry: a prospective meta-analysis from the cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium[J]. Circ Cardiovasc Genet, 2010, 3(3):256-266. doi: 10.1161/CIRCGENETICS.109.895763 URL
[4]	Morrison AC, Felix JF, Cupples LA, et al. Genomic varia-tion associated with mortality among adults of European and African ancestry with heart failure: the cohorts for heart and aging research in genomic epidemiology consortium[J]. Circ Cardiovasc Genet, 2010, 3(3):248-255. doi: 10.1161/CIRCGENETICS.109.895995 URL
[5]	Fox ER, Musani SK, Barbalic M, et al. Genome-wide association study of cardiac structure and systolic function in African Americans: the Candidate Gene Association Resource (CARe) study[J]. Circ Cardiovasc Genet, 2013, 6(1):37-46. doi: 10.1161/CIRCGENETICS.111.962365 URL
[6]	Gabisonia K, Recchia FA. Gene therapy for heart failure: new perspectives[J]. Curr Heart Fail Rep, 2018, 15(6):340-349. doi: 10.1007/s11897-018-0410-z pmid: 30238397
[7]	Maubaret CG, Salpea KD, Romanoski CE, et al. Association of TERC and OBFC1 haplotypes with mean leukocyte telomere length and risk for coronary heart disease[J]. PLoS One, 2013, 8(12):e83122.
[8]	Kark JD, Nassar H, Shaham D, et al. Leukocyte telomere length and coronary artery calcification in Palestinians[J]. Atherosclerosis, 2013, 229(2):363-368. doi: 10.1016/j.atherosclerosis.2013.05.030 URL
[9]	Willeit P, Willeit J, Brandstätter A, et al. Cellular aging reflected by leukocyte telomere length predicts advanced atherosclerosis and cardiovascular disease risk[J]. Arterioscler Thromb Vasc Biol, 2010, 30(8):1649-1656. doi: 10.1161/ATVBAHA.110.205492 pmid: 20508208
[10]	Cheng G, Wang L, Dai M, et al. Shorter leukocyte telo-mere length coupled with lower expression of telomerase genes in patients with essential hypertension[J]. Int J Med Sci, 2020, 17(14):2180-2186. doi: 10.7150/ijms.48456 URL
[11]	Paik JK, Kang R, Cho Y, et al. Association between genetic variations affecting mean telomere length and the prevalence of hypertension and coronary heart disease in Koreanss[J]. Clin Nutr Res, 2016, 5(4):249-260. doi: 10.7762/cnr.2016.5.4.249 URL
[12]	中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 急性心力衰竭诊断和治疗指南[J]. 中华心血管病杂志, 2010, 38(3):195-208.
[13]	Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci[J]. Cell Res, 2005, 15(2):97-98. doi: 10.1038/sj.cr.7290272 URL
[14]	Yim J, Cho H, Rabkin SW. Gene expression and gene associations during the development of heart failure with preserved ejection fraction in the Dahl salt sensitive model of hypertension[J]. Clin Exp Hypertens, 2018, 40(2):155-166. doi: 10.1080/10641963.2017.1346113 URL
[15]	Yin ZQ, Xing WH. Progress in gene therapy for chronic heart failure[J]. Heart Surg Forum, 2018, 21(2):E075-E083.
[16]	Albuquerque FN, Brandão AA, Silva DA, et al. Angiotensin-converting enzyme genetic polymorphism: its impact on cardiac remodeling[J]. Arq Bras Cardiol, 2014, 102(1):70-79. doi: 10.5935/abc.20130229 pmid: 24270863

组别	基因型					等位基因
组别	GG	CG	CC	P值^a)	P_HW值	G	C	P值^b)
例数	157(46.7)	143(42.6)	36(10.7)	-	0.687 1	457(68.0)	215(32.0)	-
死亡	23(14.6)	36(25.2)	9(25.0)	0.057 9	0.383 5	82(17.9)	54(25.1)	0.030 9
存活	134(85.4)	107(74.8)	27(75.0)		0.412 4	375(82.1)	161(74.9)

项目	GG基因型(n=157)	CG基因型(n=143)	CC基因型(n=36)	P值
年龄(岁)	60.02±15.85	60.22±16.23	63.86±17.29	0.421
性别(女/男)	56/101	45/98	13/23	0.699
体质量指数 (kg/m²)	23.74±4.53	24.27±4.09	25.95±5.44^a)	0.057
心率(次/min)	88±24	86±21	80±17^a)	0.130
收缩压(mmHg)	127±24	124±22	129±20	0.264
舒张压(mmHg)	79±16	78±14	80±18	0.604
谷丙转氨酶(U/L)	31.1(18.5, 67.2)	31.7(20.8, 57.9)	24.6(15.7, 46.1)	0.219^b)
谷草转氨酶(U/L)	32.8(21.9, 56.3)	30.9(22.6, 49.9)	26.0(21.3, 33.4)	0.081^b)
血肌酐(μmol/L)	101.0±59.5	103.8±66.9	95.0±42.7	0.736
血尿素氮(mmol/L)	8.08±3.72	8.72±4.88	8.50±4.68	0.439
血钾(mmol/L)	3.97±0.50	4.01±0.51	4.05±0.53	0.646
血钠(mmol/L)	140.2(137.0, 142.0)	140.4(137.2, 142.9)	140.3(137.8, 140.3)	0.810^b)
血钙(mmol/L)	2.25±0.13	2.26±0.15	2.23±0.13	0.495
D-二聚体(mg/L)	1.76±3.7	1.99±4.26	1.05±1.57	0.427
NT-proBNP(ng/L)	3 234±4 019	3 782±4 806	3 012±2 899	0.469
肌钙蛋白T(ng/L)	0.05(0.05, 0.88)	0.05(0.05, 2.00)	0.05(0.05, 0.16)	0.410^b)
肌酸激酶同工酶(U/L)	13.95(9.83, 22.38)	13.20(9.95, 19.50)	16.20(10.60, 19.00)	0.926^b)

项目	GG基因型(n=157)	CG基因型(n=143)	CC基因型(n=36)	P值
NYHA心功能分级				0.024
2级	30(19.1)	14(9.8)	8(22.2)	0.034
3级	82(52.2)	79(55.2)	23(63.9)	0.458
4级	45(28.7)	50(35.0)	5(13.9)	0.038
主要超声心动图指标
左心室舒张末期内径 (mm)	62.01±12.95	61.92±11.57	59.56±13.14	0.547
左心室收缩末期内径 (mm)	49.34±14.77	49.48±12.75	45.69±14.15	0.319
肺动脉收缩压(mmHg)	43.85±17.73	43.78±16.41	46.25±24.08	0.770
左心室射血分数 (%)	42.55±15.60	41.20±13.35	45.66±15.82	0.262
病因
缺血性心脏病	36(22.9)	41(28.7)	6(16.7)	0.282
心肌病	66(42.0)	61(42.7)	10(27.8)	0.252
心脏瓣膜病	42(26.8)	34(23.8)	11(30.6)	0.647
肺源性心脏病	12(7.6)	7(4.9)	4(11.1)	0.306
房颤	64(40.8)	52(36.4)	9(25.0)	0.198
伴发疾病
高血压病	80(51.0)	72(50.3)	20(55.6)	0.868
糖尿病	29(18.5)	42(29.4)	11(30.6)	0.058
吸烟史	50(31.8)	64(44.8)	15(41.7)	0.062

项目	GG基因型 (n=157)	CG基因型 (n=143)	CC基因型 (n=36)	P值
静脉利尿剂	93(59.2)	88(61.5)	25(69.4)	0.524
口服利尿剂	155(98.7)	133(93.0)	33(91.7)	0.014
襻利尿剂	150(95.5)	134(93.7)	34(94.3)	0.513
螺内酯	147(93.6)	133(93.0)	30(83.3)	0.116
地高辛	81(51.6)	62(43.4)	8(22.2)	0.005
血管扩张剂	71(45.2)	65(45.5)	13(36.1)	0.574
ACEI或ARB	129(82.2)	117(81.8)	27(75.0)	0.595
β受体阻滞剂	123(78.3)	120(83.9)	31(86.1)	0.372
左西孟旦	9(5.8)	12(8.4)	9(25.0)	0.004
冻干重组人脑钠肽	7(4.5)	9(6.3)	4(11.1)	0.306
多巴胺	36(22.9)	29(20.4)	6(16.7)	0.679
阿司匹林	70(44.6)	62(43.4)	9(25.0)	0.090
抗凝药	72(45.9)	72(50.3)	13(36.1)	0.297

项目	显性模型			隐性模型
项目	CG+CC(n=179)	GG(n=157)	P值	CC(n=36)	GG+CG(n=300)	P值
年龄 (岁)	60.96±16.46	60.02±15.85	0.597	63.86±17.29	60.12±16.01	0.189
性别 (女/男)	58/121	56/101	0.564	13/23	101/199	0.852
体质量指数 (kg/m²)	24.60±4.41	23.74±4.53	0.122	25.95±5.44	24.01±4.31	0.027
心率 (次/min)	85±20	88±24	0.233	80±17	87±22	0.053
收缩压 (mmHg)	125±22	127±24	0.401	129±20	125±23	0.294
舒张压 (mmHg)	78±15	79±16	0.696	80±18	78±15	0.454
谷氨酸转氨酶 (U/L)	28.4(19.0, 47.8)	31.1(18.5, 67.2)	0.919	24.6(15.7, 46.1)	30.4(19.9, 58.7)	0.093
谷草转氨酶 (U/L)	28.4(22.1, 43.7)	32.8(21.9, 56.3)	0.983	26.0(21.3, 33.4)	31.0(22.3, 51.1)	0.033
血肌酐 (μmol/L)	102.0±62.8	101.0±59.5	0.886	95.0±42.7	102.3±63.1	0.496
血尿素氮 (mmol/L)	8.68±4.83	8.08±3.72	0.210	8.50±4.68	8.39±4.32	0.881
血钾 (mmol/L)	4.01±0.51	3.97±0.50	0.404	4.05±0.53	3.99±0.51	0.505
血钠 (mmol/L)	140.4(137.4, 142.7)	140.2(137.0, 142.0)	0.860	140.3(137.8, 140.3)	140.3(137.2, 42.5)	0.594
血钙 (mmol/L)	2.25±0.15	2.25±0.13	0.982	2.23±0.13	2.26±0.14	0.265
D-二聚体 (mg/L)	1.79±3.88	1.76±3.7	0.928	1.05±1.57	1.87±3.99	0.229
NT-proBNP (ng/L)	3 634±4 506	3 234±4 019	0.409	3 012±2 899	3 497±4 415	0.544
肌钙蛋白T (ng/L)	0.05(0.05, 0.29)	0.05(0.05, 0.88)	0.891	0.05(0.05, 0.16)	0.05(0.05, 0.96)	0.195
肌酸激酶同工酶 (U/L)	13.15(9.93, 19.00)	13.95(9.83, 22.38)	0.944	16.20(10.60, 19.00)	13.1(9.61, 19.9)	0.733